Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Patients with classic Hodgkin lymphoma (cHL) that has relapsed after autologous or allogeneic transplant have limited treatment options and a poor prognosis. Immunotherapy with agents that target the PROGRAMMED DEATH 1 (PD-1) receptor have demonstrated clinical activity with durable responses in early-phase clinical trials in this patient population; however, patients with a history of allogeneic stem cell transplantation (SCT) were intentionally excluded from participation in those studies due to concerns for reactivation of graft-versus-host disease (GVHD). We describe the clinical course of two patients with advanced cHL and prior treatment with allogeneic stem cell transplantation (SCT) that were treated with the PD-1 inhibitor pembrolizumab. Both patients had no active graft-versus-host disease (GVHD) at the time initiation of therapy and were maintained on low-dose prednisone. Treatment with pembrolizumab was well tolerated and not associated with reactivation of GVHD. Both patients responded (1 partial, 1 complete) and remain on therapy as of November 30, 2015. This report indicates that immunotherapy targeting the PD-1 pathway can be safely administered to patients with cHL and a history of allogeneic SCT and produce tumor responses. Further studies in this patient population are needed.

Original languageEnglish (US)
Pages (from-to)13260-13264
Number of pages5
JournalOncotarget
Volume7
Issue number11
DOIs
StatePublished - Mar 15 2016

Fingerprint

Hodgkin Disease
Stem Cells
Transplants
Stem Cell Transplantation
Graft vs Host Disease
Immunotherapy
Therapeutics
Prednisone
Population
Clinical Trials
Neoplasms

Keywords

  • Allogeneic stem cell transplantation
  • Hodgkin lymphoma
  • Immunotherapy
  • PD-1 inhibitors
  • Pembrolizumab

ASJC Scopus subject areas

  • Oncology

Cite this

@article{a43c518086ab4393a36d051ac2980e8e,
title = "Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective",
abstract = "Patients with classic Hodgkin lymphoma (cHL) that has relapsed after autologous or allogeneic transplant have limited treatment options and a poor prognosis. Immunotherapy with agents that target the PROGRAMMED DEATH 1 (PD-1) receptor have demonstrated clinical activity with durable responses in early-phase clinical trials in this patient population; however, patients with a history of allogeneic stem cell transplantation (SCT) were intentionally excluded from participation in those studies due to concerns for reactivation of graft-versus-host disease (GVHD). We describe the clinical course of two patients with advanced cHL and prior treatment with allogeneic stem cell transplantation (SCT) that were treated with the PD-1 inhibitor pembrolizumab. Both patients had no active graft-versus-host disease (GVHD) at the time initiation of therapy and were maintained on low-dose prednisone. Treatment with pembrolizumab was well tolerated and not associated with reactivation of GVHD. Both patients responded (1 partial, 1 complete) and remain on therapy as of November 30, 2015. This report indicates that immunotherapy targeting the PD-1 pathway can be safely administered to patients with cHL and a history of allogeneic SCT and produce tumor responses. Further studies in this patient population are needed.",
keywords = "Allogeneic stem cell transplantation, Hodgkin lymphoma, Immunotherapy, PD-1 inhibitors, Pembrolizumab",
author = "{Villasboas Bisneto}, {Jose (J.C.)} and Ansell, {Stephen Maxted} and Witzig, {Thomas Elmer}",
year = "2016",
month = "3",
day = "15",
doi = "10.18632/oncotarget.7177",
language = "English (US)",
volume = "7",
pages = "13260--13264",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective

AU - Villasboas Bisneto, Jose (J.C.)

AU - Ansell, Stephen Maxted

AU - Witzig, Thomas Elmer

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Patients with classic Hodgkin lymphoma (cHL) that has relapsed after autologous or allogeneic transplant have limited treatment options and a poor prognosis. Immunotherapy with agents that target the PROGRAMMED DEATH 1 (PD-1) receptor have demonstrated clinical activity with durable responses in early-phase clinical trials in this patient population; however, patients with a history of allogeneic stem cell transplantation (SCT) were intentionally excluded from participation in those studies due to concerns for reactivation of graft-versus-host disease (GVHD). We describe the clinical course of two patients with advanced cHL and prior treatment with allogeneic stem cell transplantation (SCT) that were treated with the PD-1 inhibitor pembrolizumab. Both patients had no active graft-versus-host disease (GVHD) at the time initiation of therapy and were maintained on low-dose prednisone. Treatment with pembrolizumab was well tolerated and not associated with reactivation of GVHD. Both patients responded (1 partial, 1 complete) and remain on therapy as of November 30, 2015. This report indicates that immunotherapy targeting the PD-1 pathway can be safely administered to patients with cHL and a history of allogeneic SCT and produce tumor responses. Further studies in this patient population are needed.

AB - Patients with classic Hodgkin lymphoma (cHL) that has relapsed after autologous or allogeneic transplant have limited treatment options and a poor prognosis. Immunotherapy with agents that target the PROGRAMMED DEATH 1 (PD-1) receptor have demonstrated clinical activity with durable responses in early-phase clinical trials in this patient population; however, patients with a history of allogeneic stem cell transplantation (SCT) were intentionally excluded from participation in those studies due to concerns for reactivation of graft-versus-host disease (GVHD). We describe the clinical course of two patients with advanced cHL and prior treatment with allogeneic stem cell transplantation (SCT) that were treated with the PD-1 inhibitor pembrolizumab. Both patients had no active graft-versus-host disease (GVHD) at the time initiation of therapy and were maintained on low-dose prednisone. Treatment with pembrolizumab was well tolerated and not associated with reactivation of GVHD. Both patients responded (1 partial, 1 complete) and remain on therapy as of November 30, 2015. This report indicates that immunotherapy targeting the PD-1 pathway can be safely administered to patients with cHL and a history of allogeneic SCT and produce tumor responses. Further studies in this patient population are needed.

KW - Allogeneic stem cell transplantation

KW - Hodgkin lymphoma

KW - Immunotherapy

KW - PD-1 inhibitors

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=84962897493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962897493&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7177

DO - 10.18632/oncotarget.7177

M3 - Article

AN - SCOPUS:84962897493

VL - 7

SP - 13260

EP - 13264

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -